| Title: | Association between genetic variants and incidence of cardiac arrhythmias among patients with ischemic and nonischemic cardiomyopathy in the UK Biobank population |
| Lead Institution: | Weill Cornell Medical College |
| Principal investigator: | Dr Jim Cheung |
Application 68952
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Heart failure today remains one of the leading causes of morbidity and mortality worldwide (Mozafarrian et al. 2016). Indeed, despite significant advances in therapy, heart failure continues to carry a 5 -year mortality rate approaching 50%. As heart failure progresses, buildup of scar tissue in the heart increases the risk of unstable electrical rhythms (arrhythmias) which can be fatal. Although electrophysiological interventions such as defibrillator insertion can help lengthen mortality, it remains challenging to identify which patients are at highest risk and therefore stand to benefit the most from invasive procedures. Furthermore, in many instances the arrhythmias may be driving the heart failure in the first place, and addressing them earlier may offer significant benefit. Importantly, recent studies have shown that certain genetic mutations may increase the risk of both heart failure and cardiac arrhythmias, though the interplay between them remains unclear. Many of these studies have been limited by relatively small sample size. Fortunately, the UK Biobank is a robust dataset that has longitudinally followed hundreds of thousands of patients which can provide the statistical power to help shed light on these previously unanswered questions. By investigating the associations between genetic variants, heart failure, and cardiac arrhythmias, we can help identify which patients are at highest risk of developing cardiac arrhythmias and help providers to target interventions accordingly. This study would also help determine whether upfront genetic sequencing of patients may be of value in prognostication and risk stratification, which is currently not the standard of care given that these associations remain unclear. This would ultimately be the first study of its kind, and we hope to meet the goal of the UK Biobank and deliver significant value to public health.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 10969 | Population-Level Prevalence of Rare Variants Associated With Atrial Fibrillation and its Impact on Patient Outcomes | Manjinder S Kandola (+9) | 2023 | JACC Clinical Electrophysiology |
Enabling scientific discoveries that improve human health